Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
Dimensional US High Profitability ETF
DUHP
$12.8B
| $775K | ﹤0.01% |
+29,200
| New | +$737K |
|
2627
Purple Innovation
PRPL
$28.4M
| $775K | ﹤0.01% |
11,150
+5,096
| +84% | +$367K |
|
2628
Savara
SVRA
$1.08B
| $774K | ﹤0.01% |
242,300
+141,600
| +141% | +$333K |
|
|
OLK
2629
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $774K | ﹤0.01% |
+41,300
| New | +$855K |
|
2630
ThredUp
TDUP
$416M
| $772K | ﹤0.01% |
316,512
+24,312
| +8% | +$63.7K |
|
2631
The ONE Group
STKS
$56.5M
| $771K | ﹤0.01% |
105,300
-4,800
| -4% | -$36.4K |
|
|
TMHC
2632
DELISTED
Taylor Morrison
TMHC
| $768K | ﹤0.01% |
15,753
-3,400
| -18% | -$146K |
|
|
BNR
2633
Burning Rock Biotech
BNR
$105M
| $766K | ﹤0.01% |
35,610
-680
| -2% | -$18K |
|
2634
ProShares Ultra QQQ
QLD
$14.4B
| $766K | ﹤0.01% |
23,800
-26,200
| -52% | -$709K |
|
2635
UroGen Pharma
URGN
$2.39B
| $766K | ﹤0.01% |
74,000
+26,000
| +54% | +$287K |
|
2636
Greenwich LifeSciences
GLSI
$248M
| $764K | ﹤0.01% |
79,200
+28,400
| +56% | +$318K |
|
2637
CVD Equipment Corp
CVV
$52.1M
| $763K | ﹤0.01% |
103,582
+6,700
| +7% | +$59.9K |
|
2638
Third Coast Bancshares
TCBX
$758M
| $763K | ﹤0.01% |
48,100
+9,500
| +25% | +$147K |
|
|
LUMO
2639
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $763K | ﹤0.01% |
231,159
+1,245
| +0.5% | +$4.39K |
|
|
TUYA
2640
Tuya Inc
TUYA
$1.1B
| $762K | ﹤0.01% |
403,300
-19,400
| -5% | -$37.3K |
|
2641
Viant Technology
DSP
$264M
| $760K | ﹤0.01% |
164,900
+12,600
| +8% | +$55.8K |
|
|
ATXS
2642
DELISTED
Astria Therapeutics
ATXS
| $759K | ﹤0.01% |
91,061
+42,761
| +89% | +$493K |
|
2643
Clean Energy Fuels
CLNE
$384M
| $759K | ﹤0.01% |
+153,000
| New | +$670K |
|
2644
Silicom
SILC
$268M
| $759K | ﹤0.01% |
20,600
+4,474
| +28% | +$159K |
|
|
CELL
2645
DELISTED
PhenomeX Inc. Common Stock
CELL
| $758K | ﹤0.01% |
1,546,663
+274,100
| +22% | +$224K |
|
2646
Pediatrix Medical
MD
$2.15B
| $757K | ﹤0.01% |
53,300
-55,900
| -51% | -$785K |
|
2647
Direxion Daily Small Cap Bear 3x ETF
TZA
$199M
| $757K | ﹤0.01% |
+2,880
| New | +$898K |
|
2648
Valley National Bancorp
VLY
$8.25B
| $756K | ﹤0.01% |
+97,509
| New | +$776K |
|
2649
Grupo Cibest SA
CIB
$22.6B
| $755K | ﹤0.01% |
28,300
+11,900
| +73% | +$310K |
|
|
OPLN
2650
Openlane
OPLN
$4.34B
| $755K | ﹤0.01% |
+49,600
| New | +$723K |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.